ReviewCurrent atherosclerosis reports2001
The benefits of niacin in atherosclerosis.
Review in Current atherosclerosis reports, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 98 citations in OpenAlex.
- Hydroxycarboxylic acid receptor 2 (GPR109A) and retinopathies: pathways and prospects.Frontiers in medicine · 2026Review
- Niacin inhibits vascular calcification via modulating of SIRT1/SIRT6 signaling pathway.Cell death discovery · 2025Article
- Dietary niacin intake and mortality outcomes in hypertensive populations: analysis from NHANES 2003-2016.Journal of health, population, and nutrition · 2025Article
- The Effects of Niacin on Inflammation in Patients with Non-ST Elevated Acute Coronary Syndrome.Acta Cardiologica Sinica · 2015Article
- Trust your gut: galvanizing nutritional interest in intestinal cholesterol metabolism for protection against cardiovascular diseases.Nutrients · 2013Review
- Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats.Molecular biology reports · 2009Article
- Human epidermoid A431 cells express functional nicotinic acid receptor HM74a.Molecular and cellular biochemistry · 2007Article
- The effects of combined treatment with niacin and chromium on the renal tissues of hyperlipidemic rats.Molecular and cellular biochemistry · 2007Article
- Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.The Journal of clinical investigation · 2005Article
- HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease.The Clinical biochemist. Reviews · 2004Article
- Niacin, lipids, and heart disease.Current cardiology reports · 2003Review
- Toxicity of antilipidemic agents: facts and fictions.Current atherosclerosis reports · 2003Review
- Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.Drugs · 2003Review
- Beneficial effects of a novel IH636 grape seed proanthocyanidin extract and a niacin-bound chromium in a hamster atherosclerosis model.Molecular and cellular biochemistry · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Niacin favorably alters all major lipid subfractions at pharmacologic doses. Alone or in combination, it promotes regression of coronary artery disease, decreases coronary events, stroke, and total mortality. Major recent progress in niacin is in four areas. Firstly, recent data indicate that it increases high-density lipoprotein (HDL) and lowers triglycerides and low-density lipoprotein (LDL) by mechanisms different from statins, fibrates, and bile-sequestrants, giving rationale for combination therapy to achieve synergistic effects for complete lipid goal achievement. Secondly, new data on an extended-release preparation of niacin given once nightly indicates that it is as effective and has greater tolerability than immediate-release niacin. Thirdly, preliminary data with a single tablet formulation extended-release niacin and an HMG CoA reductase inhibitor (lovastatin) shows it to be safe and very effective, especially for raising HDL. Finally, emerging evidence indicates that niacin can be used effectively and safely in patients with type 2 diabetes mellitus, who often have low HDL levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.